CA2858962C - Compositions of human tear lipocalin muteins and methods of use thereof - Google Patents

Compositions of human tear lipocalin muteins and methods of use thereof Download PDF

Info

Publication number
CA2858962C
CA2858962C CA2858962A CA2858962A CA2858962C CA 2858962 C CA2858962 C CA 2858962C CA 2858962 A CA2858962 A CA 2858962A CA 2858962 A CA2858962 A CA 2858962A CA 2858962 C CA2858962 C CA 2858962C
Authority
CA
Canada
Prior art keywords
amino acid
fragment
lipocalin mutein
acid position
lipocalin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2858962A
Other languages
English (en)
French (fr)
Other versions
CA2858962A1 (en
Inventor
Andreas Hohlbaum
Laurent Audoly
Beverly Koller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pieris Pharmaceuticals GmbH
AstraZeneca AB
Original Assignee
Pieris Pharmaceuticals GmbH
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Pharmaceuticals GmbH, AstraZeneca AB filed Critical Pieris Pharmaceuticals GmbH
Publication of CA2858962A1 publication Critical patent/CA2858962A1/en
Application granted granted Critical
Publication of CA2858962C publication Critical patent/CA2858962C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA2858962A 2011-12-13 2012-12-12 Compositions of human tear lipocalin muteins and methods of use thereof Active CA2858962C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161570018P 2011-12-13 2011-12-13
US61/570,018 2011-12-13
PCT/EP2012/075146 WO2013087660A1 (en) 2011-12-13 2012-12-12 Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors

Publications (2)

Publication Number Publication Date
CA2858962A1 CA2858962A1 (en) 2013-06-20
CA2858962C true CA2858962C (en) 2023-09-05

Family

ID=47552959

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2858962A Active CA2858962C (en) 2011-12-13 2012-12-12 Compositions of human tear lipocalin muteins and methods of use thereof

Country Status (13)

Country Link
US (6) US9572863B2 (enExample)
EP (3) EP3842058B1 (enExample)
JP (5) JP6163162B2 (enExample)
CN (2) CN109432402B (enExample)
AU (1) AU2012350660B2 (enExample)
CA (1) CA2858962C (enExample)
DK (2) DK3453400T3 (enExample)
ES (2) ES2863410T3 (enExample)
HU (2) HUE054342T2 (enExample)
PL (2) PL3453400T3 (enExample)
SG (2) SG10201604566QA (enExample)
TR (1) TR201901826T4 (enExample)
WO (1) WO2013087660A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011263786B2 (en) 2010-06-08 2014-11-13 Astrazeneca Ab Tear lipocalin muteins binding IL-4 R alpha
WO2013087660A1 (en) * 2011-12-13 2013-06-20 Pieris Ag Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
CA2949405C (en) * 2014-05-22 2023-08-01 Pieris Pharmaceuticals Gmbh Novel specific-binding polypeptides and uses thereof
CA2988831A1 (en) 2015-07-15 2017-01-19 Pieris Pharmaceuticals Gmbh Novel proteins specific for lag-3
CN113372446A (zh) * 2016-06-08 2021-09-10 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
RU2019122482A (ru) 2017-01-18 2021-02-19 Пирис Фармасьютикалс Гмбх Мутеины липокалина с аффинностью связывания в отношении lag-3
CA3059731A1 (en) * 2017-04-21 2018-10-25 Kindred Biosciences, Inc. Il4/il13 receptor molecule for veterinary use
CN111494625B (zh) 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
US20220168387A1 (en) * 2019-03-29 2022-06-02 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
CA3133422A1 (en) * 2019-03-29 2020-10-08 Astrazeneca Ab Lipocalin mutein for treatment of asthma
TW202241490A (zh) 2020-12-18 2022-11-01 瑞典商阿斯特捷利康公司 用於治療氣喘之脂質運載蛋白突變蛋白乾粉配製物
CN115414467B (zh) * 2022-10-14 2023-06-06 中国人民解放军陆军军医大学第二附属医院 载脂蛋白d在制备治疗脑出血药物中的用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
DE4425255A1 (de) 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6446467B1 (en) 1997-07-29 2002-09-10 Physical Optics Corporation Monolithic glass light shaping diffuser and method for its production
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
CN1170543C (zh) 1998-06-08 2004-10-13 弗·哈夫曼-拉罗切有限公司 PEG-IFN-α和三唑核苷在治疗慢性丙型肝炎中的用途
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
DE10043509A1 (de) 2000-09-01 2002-03-14 Asta Medica Ag Feste Peptidzubereitungen für die Inhalation und deren Herstellung
EP1377306A1 (en) 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
EP1430136A1 (en) 2001-09-27 2004-06-23 Pieris ProteoLab AG Muteins of apolipoprotein d
AU2003233583A1 (en) * 2002-05-24 2003-12-12 Agennix Incorporated Oral lactoferrin in the treatment of respiratory disorders
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
RU2389796C2 (ru) 2003-08-29 2010-05-20 Аэровэнс, Инк. Модифицированный антагонист рецептора il-4 и предназначенный для его получения очищенный полинуклеотид
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
WO2007038619A2 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
US8598317B2 (en) 2006-03-20 2013-12-03 Technische Universitaet Muenchen Muteins of tear lipocalin with affinity for the T-cell coreceptor CD4
SG173332A1 (en) 2006-08-01 2011-08-29 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
CN101784280A (zh) * 2007-07-11 2010-07-21 艾罗文斯公司 药物多肽干粉气溶胶制剂及制备方法
AU2011263786B2 (en) 2010-06-08 2014-11-13 Astrazeneca Ab Tear lipocalin muteins binding IL-4 R alpha
WO2013087660A1 (en) * 2011-12-13 2013-06-20 Pieris Ag Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors

Also Published As

Publication number Publication date
CN103998053B (zh) 2018-11-02
US20190030121A1 (en) 2019-01-31
US10016483B2 (en) 2018-07-10
AU2012350660A1 (en) 2014-07-03
EP2790719B1 (en) 2018-11-21
EP3842058A1 (en) 2021-06-30
US20210145934A1 (en) 2021-05-20
TR201901826T4 (tr) 2019-03-21
EP3453400B1 (en) 2021-01-20
CN103998053B9 (zh) 2020-07-21
US10398754B2 (en) 2019-09-03
JP6889201B2 (ja) 2021-06-18
SG11201402992SA (en) 2014-07-30
JP6163162B2 (ja) 2017-07-12
HUE042720T2 (hu) 2019-07-29
JP6725447B2 (ja) 2020-07-15
WO2013087660A1 (en) 2013-06-20
US10857202B2 (en) 2020-12-08
US9572863B2 (en) 2017-02-21
DK2790719T3 (en) 2019-02-11
ES2710384T3 (es) 2019-04-24
AU2012350660B2 (en) 2018-01-25
US20230021168A1 (en) 2023-01-19
EP3453400A1 (en) 2019-03-13
US11382951B2 (en) 2022-07-12
US20200009223A1 (en) 2020-01-09
HUE054342T2 (hu) 2021-08-30
PL3453400T3 (pl) 2021-08-09
EP3842058B1 (en) 2023-08-23
SG10201604566QA (en) 2016-07-28
CN109432402B (zh) 2022-04-29
JP2015505303A (ja) 2015-02-19
US20140357548A1 (en) 2014-12-04
JP2017149733A (ja) 2017-08-31
PL2790719T3 (pl) 2019-05-31
ES2863410T3 (es) 2021-10-11
DK3453400T3 (da) 2021-04-06
JP2019116499A (ja) 2019-07-18
JP7441589B2 (ja) 2024-03-01
JP2020164532A (ja) 2020-10-08
US20170112900A1 (en) 2017-04-27
EP2790719A1 (en) 2014-10-22
CA2858962A1 (en) 2013-06-20
CN109432402A (zh) 2019-03-08
CN103998053A (zh) 2014-08-20
JP2022084854A (ja) 2022-06-07

Similar Documents

Publication Publication Date Title
US11382951B2 (en) Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptors
EP1849478A2 (en) Inflammatory mediator antagonists
JP6087429B2 (ja) 変形されたヒト腫瘍壊死因子受容体−１ポリペプチドの新規用途
HK40051700A (en) Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
HK40004111B (en) Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
HK40004111A (en) Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
HK40001660A (en) Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
HK40001660B (en) Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
CN106540242B (zh) IL-1F7a的作用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171124

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251008